CHINAPLAS
12.3.2019 03:02:11 CET | Business Wire | Press release
The operating environment for most industries became increasingly complex. It is more vital than ever for enterprising businesses to master technological innovation. CHINAPLAS , the Asia’s No. 1 plastics and rubber trade fair, offers an international platform for the release and exchange of advanced new technologies. The show will not only feature more than 3,500 exhibitors but will also organize a series of exciting concurrent events to address those industries’ needs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190311005047/en/
Plastics Recycling & Circular Economy Conference and Showcase
To foster circular economy is a global consensus to achieve sustainable development. Great potential and bounteous market opportunities arise with it. More and more big brands have announced environmental protection policies of recycling. In 2017, Adidas sold 1 million pairs of running shoes made of ocean plastic waste. How can plastics contribute to sustainable development? Focusing on the concerns of the industry, a “Plastics Recycling & Circular Economy Conference and Showcase ”, will be held with the themes of “Material Science for Sustainability”, “Recycling Technology” and “Environmental Packaging”.
Industry 4.0 Factory of the Future
Industry practitioners can visit the “Industry 4.0 Factory of the Future ” at CHINAPLAS 2019. There will be two themed areas, “Manufacturing Intelligence Control Room” and “Smart Factory”, to demonstrate implementable intelligent solutions. The control room will display operational data recorded at both the on-site machines and a remote smart factory, while the “Smart Factory” will simulate the future manufacturing environment.
Design x Innovation
Recognizing the key role of design in product development, CHINAPLAS 2019 will organize the event “Design x Innovation ”, comprising three parts.
1. CMF Inspiration Walls will display rich resources on Color, Material and Finish.
2. Design Forum will share product experience covering recyclable & sustainable design, low carbon design and CMF applications.
3. CHINAPLAS Designers’ Night .
Tech Talk
By way of open forums, “Tech Talk ” will showcase the hottest product technologies, and focus clearly on cutting-edge solutions. Tech Talk will include 11 major themes, including new energy vehicles, automotive thermoplastic elastomers, 3D printing, Bioplastics, composites, antimicrobial applications, in-mold labeling, precision extrusion, green building solutions, plastics for wearable electronics, long fiber injection molding.
Medical Plastics Connect
“Medical Plastics Connect ” actively promotes medical-grade chemical raw materials and equipment to create an efficient communication platform for medical device, consumables, and pharmaceutical packaging manufacturers. These activities aim to pinpoint for potential buyers the unique medical plastics technologies among the many exhibits active in this sector. "Medical Plastics Connect” activities include “Open Forum”, “Pop-up Kiosk”, “Medical Plastics Guidebook” and “Medical Plastics Guided Tour”.
CHINAPLAS , the Asia’s No. 1 plastics and rubber trade fair, will be held in Guangzhou, PR China, from May 21-24, 2019. An estimated total of over 3,500 exhibitors from all over the world will be presenting to more than 180,000 professional visitors from 150 countries and regions. For more information and pre-registration, please click here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190311005047/en/
Contact:
Stella Yuen Chinaplas.PR@adsale.com.hk
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom